Trifluoperazine-d3 dihydrochloride

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白、同位素标记物，专注于信号通路和疾病研究领域。
Trifluoperazine-d3 dihydrochloride 

Trifluoperazine-d3 (dihydrochloride) 是 Trifluoperazine (dihydrochloride) 氘代物。Trifluoperazine dihydrochloride 是一种抗精神病药物，通过阻断中枢多巴胺受体 (dopamine receptors) 起作用。Trifluoperazine dihydrochloride 是一种有效的 α1-adrenergic 受体拮抗剂。Trifluoperazine dihydrochloride 是一种有效的 NUPR1 抑制剂，具有抗癌活性。Trifluoperazine dihydrochloride是一种钙调蛋白 (calmodulin) 抑制剂，还可抑制 P-糖蛋白 (P-glycoprotein)，可用于精神分裂症的研究。Trifluoperazine dihydrochloride 是流感病毒 (influenza virus) 形态发生的可逆抑制剂。

Trifluoperazine-d3 dihydrochloride

Trifluoperazine-d3 dihydrochloride Chemical Structure

CAS No. : 1432064-02-2

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Trifluoperazine-d3 (dihydrochloride) is deuterium labeled Trifluoperazine (dihydrochloride). Trifluoperazine dihydrochloride, an antipsychotic agent, acts by blocking central dopamine receptors. Trifluoperazine dihydrochloride is a potent α1-adrenergic receptor antagonist. Trifluoperazine dihydrochloride is a potent NUPR1 inhibitor exerting anticancer activity. Trifluoperazine dihydrochloride is a calmodulin inhibitor, and also inhibits P-glycoprotein. Trifluoperazine dihydrochloride can be used for the research of schizophrenia. Trifluoperazine dihydrochloride acts as a reversible inhibitor of influenza virus morphogenesis[1][2][3][4][5].

体外研究
(In Vitro)

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

483.44

Formula

C21H23D3Cl2F3N3S
CAS 号

1432064-02-2
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

    [2]. Santofimia-Castaño P, et al. Ligand-based design identifies a potent NUPR1 inhibitor exerting anticancer activity via necroptosis. J Clin Invest. 2019;129(6):2500-2513. Published 2019 Mar 28.

    [3]. Huerta-Bahena J, Villalobos-Molina R, García-Sáinz JA. Trifluoperazine and chlorpromazine antagonize alpha 1- but not alpha2- adrenergic effects. Mol Pharmacol. 1983;23(1):67-70.

    [4]. Marques LO, Lima MS, Soares BG. Trifluoperazine for schizophrenia. Cochrane Database Syst Rev. 2004;2004(1):CD003545.

    [5]. Howland RH. Trifluoperazine: A Sprightly Old Drug. J Psychosoc Nurs Ment Health Serv. 2016;54(1):20-22.

    [6]. Ochiai H, et al. Influence of trifluoperazine on the late stage of influenza virus infection in MDCK cells. Antiviral Res. 1991;15(2):149-160.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务